Testing icotrokinra for moderate to severe Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This study tests a new medicine called icotrokinra for people with moderate to severe Crohn's disease who have not responded well to other treatments. It aims to see if icotrokinra can help reduce symptoms and improve gut health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with Crohn's disease at least 12 weeks before the study starts.
- Your Crohn's disease must be moderately to severely active, based on symptom scores and a colonoscopy.
- You must have tried at least one conventional therapy (like steroids or immune suppressants) without success, or you cannot tolerate them.
- If you are a woman who could become pregnant, you must have negative pregnancy tests and agree to use effective birth control.
- You cannot have certain complications like a blocked intestine or a stoma (surgical opening in the abdomen), and you cannot have had recent colon surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing multiple new drugs for people with moderate to severe ulcerative colitis or Crohn's disease who have not had success with at least one standard treatment. The goal is to find a better option that can help control symptoms and inflammation.
This study tests a new drug called JNJ-78934804 for people with moderate to severe Crohn's disease who have not responded well to or can't tolerate current treatments. The goal is to see if this drug can reduce inflammation and symptoms in the digestive tract.
This trial tests a new oral medication, icotrokinra, for people with moderately to severely active ulcerative colitis. It may be an option if you have not responded well enough to standard treatments or newer advanced therapies.
This trial tests a new medication called icotrokinra for people with active psoriatic arthritis (PsA). It aims to see how well the drug works and if it is safe, including for those who have tried other treatments.
This study tests an experimental drug called SAR442970 for people with moderate to severe Crohn's disease who haven't had success with standard treatments or biologics. The goal is to see if it can reduce inflammation and improve symptoms.
This trial is testing a new investigational treatment called TRX103 for adults with moderate to severe Crohn's disease that has not responded to at least two other advanced therapies. The study aims to see if this treatment can reduce inflammation and improve symptoms.
Hear when a new Crohn Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.